Evidence map›Paper›PMID 29128351›Full record

ArticleBone2018

Drosophila models of FOP provide mechanistic insight.

Viet Le, Edward Anderson, Takuya Akiyama, Kristi A Wharton

Abstract read
In one paragraph

Article in Bone, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Viet LeDepartment of Molecular Biology, Cell Biology, and Biochemistry, Brown University, Providence, RI, USA; Program in Molecular Medicine, Boston Children's Hospital and Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA.
Edward AndersonDepartment of Molecular Biology, Cell Biology, and Biochemistry, Brown University, Providence, RI, USA.
Takuya AkiyamaDepartment of Molecular Biology, Cell Biology, and Biochemistry, Brown University, Providence, RI, USA; Stowers Institute for Medical Research, Kansas City, MO, USA.
Kristi A WhartonDepartment of Molecular Biology, Cell Biology, and Biochemistry, Brown University, Providence, RI, USA. Electronic address: Kristi_Wharton@brown.edu.
Brown University · USBoston Children's Hospital · US

Funding

TRAINING IN MOLECULAR &CELL BIOLOGY &BIOCHEMISTRYT32GM007601 · NIGMS · BROWN UNIVERSITY · PI MOWRY, KIMBERLY L. · 1985 to 2019
$6.4M
Differential regulation of BMP Signals in VivoR01GM068118 · NIGMS · BROWN UNIVERSITY · PI WHARTON, KRISTI A · 2005 to 2014
$2.5M
Differential regulation of BMP signals in vivo.R56GM068118 · NIGMS · BROWN UNIVERSITY · PI WHARTON, KRISTI A · 2009 to 2009
$352k
NIGMS NIH HHS R01 GM068118NIGMS NIH HHS R56 GM068118NIGMS NIH HHS T32 GM007601
6 · The paper itself

Abstract

Fibrodysplasia ossificans progressiva (FOP) is a rare bone disease characterized by episodic events of heterotopic ossification (HO). All cases of FOP have been attributed to mutations in the ACVR1 gene that render the encoded BMP type I ALK2 receptor hypersensitive, resulting in the activation of BMP signaling, at inappropriate times in inappropriate locations. The episodic or sporadic nature of HO associated with FOP rests with the occurrence of specific 'triggers' that push the hypersensitive ALK2-FOP receptor into full signaling mode. Identification of these triggers and their mechanism of action is critical for preventing HO and its devastating consequences in FOP patients. Models of FOP, generated in Drosophila, are shown to activate the highly conserved BMP signaling pathway in both Drosophila cell culture and in developing tissues in vivo. The most common FOP mutation, R206H, in ALK2 and its synonymous mutation, K262H, in the orthologous Drosophila receptor Sax, abolish the ability of wild type receptors to inhibit BMP ligand-induced signaling and lead to ubiquitous pathway activation in both cases but with important differences. When expressed in Drosophila, human ALK2

Indexed as

Activin Receptors, Type IAnimalsDrosophilaDrosophila ProteinsMutationMyositis OssificansReceptors, Transforming Growth Factor betaSignal TransductionActivin Receptors, Type IDrosophila ProteinsReceptors, Transforming Growth Factor betasax protein, DrosophilaACVR1ALK2BMP signalingFibrodysplasia Ossificans ProgressivaHeterotopic ossificationSax

Identifiers

PMID29128351
PMCPMC11957552
OpenAlexW2767487493

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.